GO-COLITIS Trial in Ulcerative Colitis Patients Shows Simponi Induces Positive Clinical Response

GO-COLITIS Trial in Ulcerative Colitis Patients Shows Simponi Induces Positive Clinical Response
Janssen Pharmaceutical's Simponi (golimumab) induced a clinical response in more than two-thirds of patients with moderate to severe ulcerative colitis in the induction phase of the GO-COLITIS clinical trial, according to the study “Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study (DOP049),” recently prese
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *